deltatrials
Unknown PHASE2 INTERVENTIONAL 2-arm NCT04591431

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME)

Sponsor: Fondazione per la Medicina Personalizzata

Conditions Breast Cancer Gastrointestinal Cancer Non Small Cell Lung Cancer Other Cancer
Interventions Alectinib Alpelisib Atezolizumab Brigatinib Cobimetinib Entrectinib Erlotinib Everolimus Ipatasertib Ipilimumab Itacitinib Lapatinib Nivolumab Oncology Drugs Palbociclib Pemigatinib Pertuzumab Ponatinib Pralsetinib Selpercatinib Talazoparib Tepotinib Trastuzumab Trastuzumab emtansine Vemurafenib Vismogedib
Updated 17 times since 2020 Last updated: Oct 2, 2023 Started: Oct 7, 2020 Primary completion: Dec 31, 2024 Completion: Jun 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Breast Cancer and Gastrointestinal Cancer and is currently ongoing. Fondazione per la Medicina Personalizzata leads this study, which shows 17 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Dec 2021 · 6 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Feb 2023 · 9 months · monthly snapshot~Feb 2023 – ~May 2023 · 3 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Nov 2023 · 5 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – present · 7 months · monthly snapshot

Change History

17 versions recorded

  1. Nov 2025 — Present [monthly]

    Unknown PHASE2

    Status: Active Not Recruiting → Unknown

  2. Sep 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Nov 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 12 earlier versions

  1. Jun 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  3. Feb 2023 — May 2023 [monthly]

    Recruiting PHASE2

  4. May 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  5. Mar 2022 — May 2022 [monthly]

    Recruiting PHASE2

  6. Dec 2021 — Mar 2022 [monthly]

    Recruiting PHASE2

  7. Jun 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  8. Mar 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  9. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  10. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  11. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Nov 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Oct 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fondazione per la Medicina Personalizzata
Data source: Fondazione per la Medicina Personalizzata

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ancona, Italy , Aviano, Italy , Bari, Italy , Bergamo, Italy , Bologna, Italy , Carpi, Italy , Catania, Italy , Catanzaro, Italy , Ferrara, Italy , Genova, Italy and 20 more locations